Sign Up for a Free Account
  • Updated 12.08.2023
  • Released 07.07.2021
  • Expires For CME 12.08.2026

Personal approach to multiple sclerosis treatment



In this article, the author discusses her personal approach to treating individuals with multiple sclerosis. Multiple sclerosis is the major acquired CNS disease of young adults. Untreated, it can lead to permanent disability. There are two primary disease forms: relapsing and progressive. Relapsing multiple sclerosis is characterized by focal inflammation leading to neurologic attacks (also called relapses, exacerbations, or flare-ups). There is acute onset of neurologic deficits over hours to days, followed by a typical recovery period (recovery is generally complete early in the disease process, and incomplete later). Individuals are clinically stable between relapses. Progressive multiple sclerosis is characterized by smoldering inflammation/neurodegeneration that results in slow worsening, with gradual accumulating deficits apparent over months at a time.

Since 1993, multiple disease-modifying therapies have been developed and approved to treat, in particular, relapsing forms of multiple sclerosis. Choosing the optimal disease-modifying therapy is key. Other treatment domains involve management of acute relapses, multiple sclerosis symptoms, and steps to enhance CNS reserve (optimized lifestyle choices, a comprehensive wellness program, and identification and optimized management of damaging comorbidities). Therapeutic multiple sclerosis principles are emerging. Treatment is changing the natural history of this disease and will, hopefully, allow most individuals to lead a normal life.

Key points

• Untreated multiple sclerosis involves accumulating permanent damage to the CNS.

• For most individuals, multiple sclerosis is a highly treatable disease.

• Early treatment is important.

This is an article preview.
Start a Free Account
to access the full version.

  • Nearly 3,000 illustrations, including video clips of neurologic disorders.

  • Every article is reviewed by our esteemed Editorial Board for accuracy and currency.

  • Full spectrum of neurology in 1,200 comprehensive articles.

  • Listen to MedLink on the go with Audio versions of each article.

Questions or Comment?

MedLink®, LLC

3525 Del Mar Heights Rd, Ste 304
San Diego, CA 92130-2122

Toll Free (U.S. + Canada): 800-452-2400

US Number: +1-619-640-4660



ISSN: 2831-9125